FI3645002T3 - Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla - Google Patents
Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla Download PDFInfo
- Publication number
- FI3645002T3 FI3645002T3 FIEP18745732.0T FI18745732T FI3645002T3 FI 3645002 T3 FI3645002 T3 FI 3645002T3 FI 18745732 T FI18745732 T FI 18745732T FI 3645002 T3 FI3645002 T3 FI 3645002T3
- Authority
- FI
- Finland
- Prior art keywords
- period
- csa
- weeks
- subject
- initial
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 9
- 206010019280 Heart failures Diseases 0.000 title claims 6
- 239000012190 activator Substances 0.000 title claims 2
- 230000000747 cardiac effect Effects 0.000 title claims 2
- 210000002235 sarcomere Anatomy 0.000 title claims 2
- 230000036470 plasma concentration Effects 0.000 claims 17
- 230000000977 initiatory effect Effects 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527983P | 2017-06-30 | 2017-06-30 | |
| PCT/US2018/040181 WO2019006235A1 (en) | 2017-06-30 | 2018-06-29 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3645002T3 true FI3645002T3 (fi) | 2025-01-29 |
Family
ID=63013097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18745732.0T FI3645002T3 (fi) | 2017-06-30 | 2018-06-29 | Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11576910B2 (https=) |
| EP (2) | EP3645002B1 (https=) |
| JP (3) | JP2020526483A (https=) |
| CN (1) | CN110996953A (https=) |
| AU (2) | AU2018290983B2 (https=) |
| BR (1) | BR112019028046A2 (https=) |
| CA (1) | CA3068588A1 (https=) |
| DK (1) | DK3645002T3 (https=) |
| ES (1) | ES3008457T3 (https=) |
| FI (1) | FI3645002T3 (https=) |
| HR (1) | HRP20241729T1 (https=) |
| HU (1) | HUE069805T2 (https=) |
| LT (1) | LT3645002T (https=) |
| MA (1) | MA49508B1 (https=) |
| MD (1) | MD3645002T2 (https=) |
| MX (2) | MX2020000190A (https=) |
| PL (1) | PL3645002T3 (https=) |
| PT (1) | PT3645002T (https=) |
| RS (1) | RS66581B1 (https=) |
| SI (1) | SI3645002T1 (https=) |
| SM (1) | SMT202500067T1 (https=) |
| WO (1) | WO2019006235A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507258PA (en) | 2013-03-14 | 2015-10-29 | Amgen Inc | Heterocyclic compounds and their uses |
| AU2018294254C1 (en) | 2017-06-30 | 2022-10-13 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| DK3645002T3 (da) * | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
| PT3594199T (pt) | 2018-07-09 | 2020-09-04 | Amgen Inc | 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação |
| MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
| KR20220009440A (ko) * | 2019-05-19 | 2022-01-24 | 미요카디아, 인크. | 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료 |
| US20230090391A1 (en) * | 2020-02-10 | 2023-03-23 | Amgen Inc. | Omecamtiv mecarbil tablet |
| WO2021257456A1 (en) * | 2020-06-15 | 2021-12-23 | MyoKardia, Inc. | Treatment of atrial dysfunction |
| DK4243825T3 (da) * | 2020-11-12 | 2025-12-01 | Amgen Inc | Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper |
| CN116710139A (zh) * | 2020-11-12 | 2023-09-05 | 安进股份有限公司 | 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法 |
| IL305751A (en) | 2021-03-10 | 2023-11-01 | Amgen Inc | SYNTHESIS OF OMECAMTIV MECARBIL |
| US20250161298A1 (en) * | 2022-02-22 | 2025-05-22 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| JP2025534288A (ja) | 2022-09-26 | 2025-10-15 | エッジワイズ セラピューティクス， インコーポレイテッド | １，４－ジヒドロキナゾリノン化合物およびその使用 |
| WO2024081611A1 (en) * | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| WO2026050494A1 (en) | 2024-08-29 | 2026-03-05 | Cytokinetics, Incorporated | Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| EP1053752A1 (en) | 1998-02-10 | 2000-11-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| AU2003279842A1 (en) | 2002-10-04 | 2004-05-04 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
| US20080031957A1 (en) | 2006-05-15 | 2008-02-07 | Deluca Hector F | Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| WO2008130158A1 (en) | 2007-04-19 | 2008-10-30 | Dong-A Pharmaceutical. Co., Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| US9895308B2 (en) * | 2013-03-14 | 2018-02-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| SG11201507258PA (en) | 2013-03-14 | 2015-10-29 | Amgen Inc | Heterocyclic compounds and their uses |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| CA3052625A1 (en) | 2017-02-06 | 2018-08-09 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| AU2018294254C1 (en) | 2017-06-30 | 2022-10-13 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| DK3645002T3 (da) | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
| PT3594199T (pt) | 2018-07-09 | 2020-09-04 | Amgen Inc | 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação |
| EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| FI3599243T3 (fi) | 2018-07-26 | 2023-06-22 | Cvie Therapeutics Ltd | 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon |
| MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| MX2021010483A (es) | 2019-03-05 | 2021-10-01 | Windtree Therapeutics Inc | Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf). |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4031541A1 (en) | 2019-09-19 | 2022-07-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041710A1 (en) | 2019-10-09 | 2022-08-17 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| WO2021070123A1 (en) | 2019-10-09 | 2021-04-15 | Dr. Reddy’S Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| EP4054588A4 (en) | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| GB201918853D0 (en) | 2019-12-19 | 2020-02-05 | Lund Lars H | Methods of treatment |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| US20230090391A1 (en) | 2020-02-10 | 2023-03-23 | Amgen Inc. | Omecamtiv mecarbil tablet |
| DK4243825T3 (da) | 2020-11-12 | 2025-12-01 | Amgen Inc | Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper |
| IL305751A (en) | 2021-03-10 | 2023-11-01 | Amgen Inc | SYNTHESIS OF OMECAMTIV MECARBIL |
| WO2023205291A2 (en) | 2022-04-21 | 2023-10-26 | The Board Of Regents Of The University Of Oklahoma | Targeting myocardial tissue for delivery of therapeutic and imaging agents |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) * | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2018
- 2018-06-29 DK DK18745732.0T patent/DK3645002T3/da active
- 2018-06-29 LT LTEPPCT/US2018/040181T patent/LT3645002T/lt unknown
- 2018-06-29 SM SM20250067T patent/SMT202500067T1/it unknown
- 2018-06-29 ES ES18745732T patent/ES3008457T3/es active Active
- 2018-06-29 EP EP18745732.0A patent/EP3645002B1/en active Active
- 2018-06-29 BR BR112019028046-4A patent/BR112019028046A2/pt not_active Application Discontinuation
- 2018-06-29 EP EP24209435.7A patent/EP4512470A3/en active Pending
- 2018-06-29 AU AU2018290983A patent/AU2018290983B2/en active Active
- 2018-06-29 PL PL18745732.0T patent/PL3645002T3/pl unknown
- 2018-06-29 CA CA3068588A patent/CA3068588A1/en active Pending
- 2018-06-29 MA MA49508A patent/MA49508B1/fr unknown
- 2018-06-29 PT PT187457320T patent/PT3645002T/pt unknown
- 2018-06-29 WO PCT/US2018/040181 patent/WO2019006235A1/en not_active Ceased
- 2018-06-29 SI SI201831198T patent/SI3645002T1/sl unknown
- 2018-06-29 HR HRP20241729TT patent/HRP20241729T1/hr unknown
- 2018-06-29 HU HUE18745732A patent/HUE069805T2/hu unknown
- 2018-06-29 JP JP2019570045A patent/JP2020526483A/ja active Pending
- 2018-06-29 CN CN201880053343.0A patent/CN110996953A/zh active Pending
- 2018-06-29 MD MDE20200488T patent/MD3645002T2/ro unknown
- 2018-06-29 RS RS20250023A patent/RS66581B1/sr unknown
- 2018-06-29 US US16/625,958 patent/US11576910B2/en active Active
- 2018-06-29 FI FIEP18745732.0T patent/FI3645002T3/fi active
- 2018-06-29 MX MX2020000190A patent/MX2020000190A/es unknown
-
2020
- 2020-01-08 MX MX2022015115A patent/MX2022015115A/es unknown
-
2023
- 2023-01-17 US US18/155,483 patent/US12295952B2/en active Active
- 2023-03-15 JP JP2023040600A patent/JP2023088944A/ja active Pending
- 2023-05-05 US US18/313,267 patent/US11931358B2/en active Active
-
2024
- 2024-02-15 AU AU2024200991A patent/AU2024200991B2/en active Active
-
2025
- 2025-04-18 US US19/183,619 patent/US20250255862A1/en active Pending
- 2025-07-18 JP JP2025121073A patent/JP2025165979A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3645002T3 (fi) | Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla | |
| JP2023088944A5 (https=) | ||
| JP2020526483A5 (https=) | ||
| KR101718639B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| FI4243825T3 (fi) | Omekamtiivimekarbiili sydämen vajaatoiminnan hoitoon valikoiduilla potilasryhmillä | |
| JP2013543491A5 (https=) | ||
| JP2017513809A5 (https=) | ||
| FI3294283T3 (fi) | Sakubitriili-valsartaani-annostusohjelma sydämen vajaatoiminnan hoitamiseksi | |
| WO2003079979A3 (en) | Method for treating congestive heart failure | |
| IL316408A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| JP2022517788A (ja) | Ｐｄｅ－５阻害剤と吸入用一酸化窒素との併用薬物療法 | |
| JP2016516016A5 (https=) | ||
| NZ713295A (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| Wang et al. | The effect of B-type brain natriuretic peptide on patients with acute decompensated heart failure coexisting with lung cancer: a randomized controlled clinical trial | |
| Jiang et al. | Effects of sildenafil on prognosis in patients with pulmonary hypertension after left-sided valvular surgery | |
| MX2022006404A (es) | Composicion farmaceutica para el tratamiento de la enfermedad vascular pulmonar y/o disfuncion cardiaca en pacientes paliados con fontan. | |
| JP2016510040A5 (https=) | ||
| Lee et al. | Potassium induced cardiac standstill during conventional cardiopulmonary resuscitation in a pig model of prolonged ventricular fibrillation cardiac arrest: a feasibility study | |
| Komajda et al. | The year in cardiology 2015: heart failure. | |
| Ringgaard et al. | Esmolol does not affect circulation negatively during resuscitation | |
| Yannopoulos et al. | Controlled pauses at the initiation of sodium nitroprusside enhanced CPR facilitate neurological and cardiac recovery after 15 minutes of untreated ventricular fibrillation | |
| Sundaravel et al. | Methylene blue to the rescue in accidental treprostinil overdose | |
| Bae et al. | The potential mechanism of the detrimental effect of defibrillation prior to cardiopulmonary resuscitation in prolonged cardiac arrest model | |
| Manzi et al. | Pulmonary arterial hypertension: available treatments in the modern era | |
| Mujović et al. | Improving symptoms and functional capacity in patients with atrial fibrillation: rate-control vs rhythm-control strategy |